Distal Subungual OnychomycosisPhase 3NCT02866032
Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
A Phase 3 study testing MOB015B and Ciclopirox 80 mg/g in people with Distal Subungual Onychomycosis, run by Moberg Pharma AB at 3 sites in 3 countries.
Trial summary
The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Distal Subungual Onychomycosis
- What is being tested?
- MOB015B and Ciclopirox 80 mg/g
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 452 participants
- Where
- 3 sitesin 3 countries
- Study dates
- Sep 2016to 10 Jun 2020
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Adult, Older adult
Who may be able to join
- Males or females 18 - 75 years of age
- Distal subungual onychomycosis (DSO) of at least one of the great toenail(s) affecting 20% to 60% of the target nail
- Positive culture for dermatophytes
- Signed written informed consent
Who cannot join
- Proximal subungual onychomycosis
- Distal subungual onychomycosis of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 3 mm)
- Target toenail thickness more than 3 mm
- "Spike" of onychomycosis extending to eponychium of the target toenail
- Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
- Other conditions than DSO known to cause abnormal nail appearance
Show all 25Show fewer
- Presence of toenail infection other than dermatophytes
- Previous target toenail surgery with any residual disfigurement
- Topical treatment of the nails with other antifungal medication or medical device within 6 weeks before screening/Visit 1
- Systemic use of antifungal treatment within 6 months before screening/ Visit 1
- Severe moccasin tinea pedis
- Signs of severe peripheral circulatory insufficiency
- Uncontrolled diabetes mellitus
- Known immunodeficiency
- Participation in another clinical trial with an investigational drug or device during the previous 3 months before Baseline/ Visit 2
- Known allergy to any of the tested treatment products
- A positive pregnancy test indicating pregnancy in a woman of childbearing potential at Baseline/ Visit 2
- Females who are pregnant or breastfeeding
- Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women who are of childbearing potential and are not practicing an acceptable method of birth control, or do not plan to continue practicing an acceptable method of birth control throughout the trial
- Patients previously randomized in this study
- History of, or current drug or alcohol abuse
- Psychiatric condition that might limit the participation in the study and/or that lead to the assumption that the patient's ability to completely understand the consequences of consent is missing
- Close affiliation with the investigator (e.g. a close relative) or persons working at a study site, or patient who is an employee of the sponsor's company
- Patients who are institutionalized because of legal or regulatory order
- Any diseases or circumstances in which the patient should not participate in the study in the opinion of the investigator
Trial locations and contacts
3 sites in 3 countries.
3 sites in 3 countries
About this study
Official title: A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO).
The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
- Conditions
- Distal Subungual Onychomycosis
- Being tested
- MOB015B, Ciclopirox 80 mg/g
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MOB015BDrug
Ciclopirox 80 mg/gDrug
| Study group | Role | What they receive |
|---|---|---|
| MOB015B | Experimental | Not described Receives: Drug: MOB015B |
| Ciclopirox 80 mg/g | Active comparator | Not described Receives: Drug: Ciclopirox 80 mg/g |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete cure of the target nail defined as negative fungal culture of dermatophytes, negative direct KOH microscopy and 0% clinical disease involvement at Week 52
Measured: Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2016 (estimated)
- Study startSep 2016
- Primary completion10 Jun 2020
- Study completion10 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Distal Subungual OnychomycosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Enrolment
- 452 participants (actual)
Sponsor and investigators
- Lead sponsor
- Moberg Pharma AB
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02866032
- Sponsor's protocol ID
- MOB015B-III
- Status last verified
- Oct 2020
- First submitted
- 5 Aug 2016
- Last updated
- 6 Oct 2020
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
- ClinicalTrials.gov ID
- NCT02866032
- Acronym / sponsor ID
- MOB015B-III
- Conditions
- Distal Subungual Onychomycosis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 452 participants (actual)
- Lead sponsor
- Moberg Pharma ABIndustry (pharma, biotech, devices)
- Study start
- Sep 2016
- Primary completion
- 10 Jun 2020 (actual)
- Study completion
- 10 Jun 2020 (actual)
- First posted
- 15 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO).
The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.
Study design
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MOB015B | Experimental | Drug: MOB015B |
| Ciclopirox 80 mg/g | Active comparator | Drug: Ciclopirox 80 mg/g |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Males or females 18 - 75 years of age
- Distal subungual onychomycosis (DSO) of at least one of the great toenail(s) affecting 20% to 60% of the target nail
- Positive culture for dermatophytes
- Signed written informed consent
Key exclusion criteria (25 listed)
- Proximal subungual onychomycosis
- Distal subungual onychomycosis of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 3 mm)
- Target toenail thickness more than 3 mm
- "Spike" of onychomycosis extending to eponychium of the target toenail
- Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MOB015B | Drug | MOB015B |
| Ciclopirox 80 mg/g | Drug | Ciclopirox 80 mg/g |
Primary outcome
Complete cure of the target nail defined as negative fungal culture of dermatophytes, negative direct KOH microscopy and 0% clinical disease involvement at Week 52
Time frame: Week 52
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2020.
Related trials for Distal Subungual Onychomycosis
Recruiting
Safety and Efficacy of Next Science Gel on Toenail Fungus
Onychomycosis of Toenail
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing MOB015B and Ciclopirox 80 mg/g in people with Distal Subungual Onychomycosis, run by Moberg Pharma AB at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Germany, Poland, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete cure of the target nail defined as negative fungal culture of dermatophytes, negative direct KOH microscopy and 0% clinical disease involvement at Week 52 (time frame: Week 52). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2020.